BTS' Suga donates 5 billion won to build autism centre for children, scripts history with music-led therapy programme

BTS member Suga has made a landmark contribution to autism care in South Korea, donating 5 billion won (approximately US $3.62 million) to Seoul's Severance Hospital to support the establishment of a new treatment centre for children with autism spectrum disorder (ASD).
The hospital announced the groundbreaking of the "Min Yoon-gi Treatment Centre"—named after Suga's real name—on Friday. Set to open in September, the facility will offer long-term, personalised mental health care, including language, psychological, and behavioural therapy. It will also run integrated programmes combining clinical treatment with research.
According to Severance Hospital officials, Suga has consistently demonstrated a deep commitment to mental health causes, even while actively performing with BTS.
'Even while performing with BTS, he has donated to charities and shown a strong interest in helping young people with depression and behavioural issues. He has sought to find ways to use his music to make a positive difference,' the hospital said in an official release
Suga's involvement goes beyond financial support.
In November last year, he met with Dr Cheon Keun-ah, a leading child psychiatry expert at Severance, to better understand the needs of children with autism. This collaboration led to the creation of "MIND" — a new programme standing for Music, Interaction, Network, Diversity — which uses music therapy to help autistic children build social and emotional skills. BTS' Suga poses with the hospital authorities.
Throughout the spring, Suga volunteered at the hospital during weekends, engaging directly with children in the MIND programme. He played the guitar, taught rhythm exercises, and guided children in using music to communicate and express emotions.
Hospital officials observed significant improvements in the children's communication and cooperation abilities over the course of the programme.
Reflecting on his experience, Suga said, "I realised that music can be a powerful way to express feelings and communicate with the world. It made me happy to be part of the treatment process for children with autism. I will keep working so that more children can live as members of society."
Dr Cheon praised Suga's dedication, noting the centre's long-term mission to help autistic children become independent and respected members of the community.
Suga recently completed his 21-month mandatory military service as a social worker. His historic donation and hands-on involvement mark a new chapter in celebrity-led philanthropy and mental health advocacy in South Korea.

Try Our AI Features

Explore what Daily8 AI can do for you:

Learn with AIFact CheckingText to SpeechAI Summary

Related Articles

Business Standard

3 hours ago

• Business Standard

Eli Lilly's weekly insulin efsitora shows positive results in Phase 3

US-based pharmaceutical company Eli Lilly on Monday announced findings from the Phase 3 clinical trials for its once-weekly investigational insulin drug, efsitora alfa (efsitora), indicating positive safety and efficacy results for A1C reduction compared to daily basal insulin. While basal insulin is a long-acting insulin administered once or twice a day, efsitora is designed for once-weekly subcutaneous injection. The company also shared detailed results from the Phase 3 QWINT-1, QWINT-3 and QWINT-4 trials. The QWINT-1 trial evaluated adults initiating insulin therapy, while QWINT-3 assessed individuals previously using daily basal insulin. QWINT-4 included participants using both basal and mealtime insulin. 'In each study, efsitora met the primary endpoint of non-inferior A1C reduction compared to daily basal insulin,' the company stated. According to Lilly, in QWINT-1, efsitora reduced A1C by 1.31 per cent compared to 1.27 per cent for insulin glargine at week 52 for the efficacy estimand. In QWINT-3, the drug reduced A1C by 0.86 per cent compared to 0.75 per cent for insulin degludec at week 26. 'In QWINT-4, efsitora reduced A1C by 1.07 per cent, matching insulin glargine's reduction of 1.07 per cent at week 26 for the efficacy estimand,' Lilly added. The Phase 3 global clinical development programme for the diabetes drug began in 2022 and included over 3,000 participants with type 2 diabetes across four global registration studies. Commenting on the results, Jeff Emmick, senior vice president of product development at Lilly, said that the once-weekly insulin therapy may offer a significant advancement for people with type 2 diabetes who need insulin, by eliminating over 300 injections a year. The company added that the drug also has the potential to provide more stable glucose levels—reducing glucose variability—throughout the week. Eli Lilly now plans to submit the drug to global regulatory agencies for the treatment of type 2 diabetes in adults by the end of 2026.

Mint

4 hours ago

• Mint

BTS' Suga donates 5 billion won to build autism centre for children, scripts history with music-led therapy programme

BTS member Suga has made a landmark contribution to autism care in South Korea, donating 5 billion won (approximately US $3.62 million) to Seoul's Severance Hospital to support the establishment of a new treatment centre for children with autism spectrum disorder (ASD). The hospital announced the groundbreaking of the "Min Yoon-gi Treatment Centre"—named after Suga's real name—on Friday. Set to open in September, the facility will offer long-term, personalised mental health care, including language, psychological, and behavioural therapy. It will also run integrated programmes combining clinical treatment with research. According to Severance Hospital officials, Suga has consistently demonstrated a deep commitment to mental health causes, even while actively performing with BTS. 'Even while performing with BTS, he has donated to charities and shown a strong interest in helping young people with depression and behavioural issues. He has sought to find ways to use his music to make a positive difference,' the hospital said in an official release Suga's involvement goes beyond financial support. In November last year, he met with Dr Cheon Keun-ah, a leading child psychiatry expert at Severance, to better understand the needs of children with autism. This collaboration led to the creation of "MIND" — a new programme standing for Music, Interaction, Network, Diversity — which uses music therapy to help autistic children build social and emotional skills. BTS' Suga poses with the hospital authorities. Throughout the spring, Suga volunteered at the hospital during weekends, engaging directly with children in the MIND programme. He played the guitar, taught rhythm exercises, and guided children in using music to communicate and express emotions. Hospital officials observed significant improvements in the children's communication and cooperation abilities over the course of the programme. Reflecting on his experience, Suga said, "I realised that music can be a powerful way to express feelings and communicate with the world. It made me happy to be part of the treatment process for children with autism. I will keep working so that more children can live as members of society." Dr Cheon praised Suga's dedication, noting the centre's long-term mission to help autistic children become independent and respected members of the community. Suga recently completed his 21-month mandatory military service as a social worker. His historic donation and hands-on involvement mark a new chapter in celebrity-led philanthropy and mental health advocacy in South Korea.

NDTV

5 hours ago

• NDTV

Are Mounjaro Jabs Safe? Mass Rollout Of Weight Loss Drug To Start In UK

For the first time, general practitioners (GPs) across the United Kingdom will be allowed to give prescriptions for a popular weight loss injection - Mounjaro, or tirzepatide. The drug, sometimes referred to as "skinny jabs", is an anti-diabetic drug made by the US-based pharmaceutical company Eli Lilly. The company said that the drug saw a "positive" response in India. The UK's National Health Service (NHS) to monitor the mass rollout that will see around 220,000 people with the "greatest need" receive the weight loss jabs over the next three years. So far, people have been able to access the drug through a special weight loss service. Now, GPs can prescribe it to severely obese people and those who are suffering from other health problems. How does Mounjaro work? It slows down the process of food digestion and also lowers blood sugar, similar to other weight loss drugs like Ozempic, Wegovy and Rybelsus. Mounjaro is used to manage type 2 diabetes and aid in weight loss. Its active ingredient, tirzepatide, works by activating two hormone receptors in the gut: GLP-1 (glucagon-like peptide-1) and GIP (gastric inhibitory polypeptide). This dual mechanism helps regulate blood sugar levels and appetite. What are the potential side effects of Mounjaro? Nausea Vomiting Diarrhea Digestive discomfort Injection site irritation Earlier this month, the UK government said that women taking popular medicines for weight loss and diabetes are being reminded to use "effective contraception" while taking these medicines. Dr Alison Cave, MHRA Chief Safety Officer, said, "Skinny jabs are medicines licensed to treat specific medical conditions and should not be used as aesthetic or cosmetic treatments. They are not a quick fix to lose weight and have not been assessed to be safe when used in this way." "Our guidance offers patients a "one stop shop" for our up-to-date advice on how to use these powerful medicines safely," Cave added. Mounjaro's positive response in India The US-based pharmaceutical company said that the drug saw a "positive" response in India and beat rival Novo Nordisk in March this year to introduce its diabetes and weight-loss drug in India. Data from research firm PharmaTrac revealed that Mounjaro has sold more than 81,570 units in India, totalling about 239.4 million rupees ($2.76 million) as of May. The drug logged a 60% rise in overall sales between April and May. "Since 2020, Lilly has invested over $50 billion to increase production capacity (for global supply). We remain fully committed to meeting the demand for our medicines across the country," the company said recently.